Mr. Jacek Antas reports

HELIX BIOPHARMA CORP. ANNOUNCES ENGAGEMENT OF INDEPENDENT TRADING GROUP TO PROVIDE MARKET-MAKING SERVICES

Helix BioPharma Corp., subject to regulatory approval, has engaged the services of Independent Trading Group (ITG) Inc. to provide market-making services in accordance with Toronto Stock Exchange policies. ITG will trade shares of the company on the TSX and all other trading venues with the objective of maintaining a reasonable market and improving the liquidity of the company's common shares.

Under the agreement, ITG will receive a monthly compensation, payable in advance. The agreement is for an initial term of one month and will renew for additional one-month terms unless terminated. The agreement may be terminated by either party with 30 days of notice. There are no performance factors contained in the agreement, and ITG will not receive shares or options as compensation. ITG and the company are unrelated and unaffiliated entities, and at the time of the agreement, neither ITG nor its principals had an interest, directly or indirectly, in the securities of the company.

ITG is a Toronto-based CIRO (Canadian Investment Regulatory Organization) dealer-member that specializes in market-making, liquidity provision, agency execution, ultralow-latency connectivity and bespoke algorithmic trading solutions. Established in 1992, with a focus on market structure, execution and trading, ITG has leveraged its own proprietary technology to deliver high-quality liquidity provision and execution services to a broad array of public issuers and institutional investors.

About Helix BioPharma Corp.

Helix BioPharma is an oncology company shaping a near future where today's hard-to-treat cancers are made vincible by novel therapies that rise to the challenge. The company innovates from strength to tackle cancer's biggest, most urgent challenges with a diverse pipeline of drug candidates with great potential and a head start, honed into first- and best-in-class oncology medicines. Its pipeline is spearheaded by a clinical-stage proprietary technology platform of bio-conjugates that score with precision against prevalent CEACAM6-expressing solid tumours. Its lead candidate, Tumour Defence Breaker L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of common, hard-to-treat solid tumours, taking the brakes off anti-cancer immunity and delivering a game-changing assist to today's front-running anti-cancer therapies. L-DOS47 has completed phase Ib studies in non-small-cell lung cancer (NSCLC), with novel strategically designed bispecific ADCs targeting CEACAM6 in discovery.

Helix is listed on the TSX under the symbol HBP, on OTC Pink under the symbol HBPCD and on FWB under the symbol HBP0.

We seek Safe Harbor.